We are pleased to announce that the Polymotion® Hip Resurfacing (PHR®) IDE study has now reached 30% of its target enrolment. This reflects the strong momentum behind the study and mission to bring this next-generation hip resurfacing technology to patients in the United States.

In line with this momentum, we’ve also activated two new clinical sites, expanding access and accelerating recruitment:

• Dr. Thomas Huff – Oregon Health & Science University (Portland, OR)

• Dr. David Crawford – Joint Implant Surgeons (New Albany, OH)

   

These additions bring the total number of active sites in the study to nine, reflecting growing enthusiasm from both surgeons and patients for the Polymotion® system.

The Polymotion® Hip Resurfacing System is an investigational device designed for active patients seeking bone-conserving alternatives to traditional hip replacement. Unlike contemporary metal-on-metal technologies, the Polymotion® system combines a Vitamin E-infused polyethylene cup with a titanium-coated shell and a metal femoral cap — avoiding metal-on-metal articulation while maintaining excellent range of motion and implant stability.

The IDE study is currently active at the following clinical sites:

• Mr. Ronan Treacy and Dr. Will Peckett – King Edward VII (Bermuda)

• Dr. Thomas Gross and Dr. Coleman Fowble – Midlands Orthopaedics & Neurosurgery (Columbia, SC)

• Dr. Stephen Raterman – Florida Medical Clinic Orlando Health (Tampa, FL)

• Dr. William Macaulay, Dr. Scott Marwin, and Dr. Matthew Hepinstall – NYU Langone (New York, NY)

• Dr. Craig Della Valle – Rush University Medical Center (Chicago, IL)

• Dr. Michael Mont and Dr. Ronald Delanois – Sinai Hospital (Baltimore, MD)

• Dr. Anthony Carter – Hampton Roads Orthopaedics (Newport News, VA)

• Dr. Thomas Huff – Oregon Health & Science University (Portland, OR)

• Dr. David Crawford – Joint Implant Surgeons (New Albany, OH)

   

We’re grateful to our investigators and clinical partners for their dedication and enthusiasm as we continue building progress towards full enrolment.

This reflects both the clinical interest in metal-free resurfacing options and the potential benefit the Polymotion® may have for younger, active patients, particularly women and smaller sized patients, who have been underrepresented in hip resurfacing due to metal-on-metal concerns.

JointMedica’ s Chief Commercial Officer Tim Band stated “Reaching 30% enrolment in the PHR® IDE study is a strong validation of both the clinical need and the enthusiasm surrounding the Polymotion® system. We are proud to see growing adoption among top orthopaedic centres and continued interest from patients who seek bone-preserving solutions without the risks associated with metal-on-metal implants. Thank you to all surgeons and patients who are participating in the study.”

We look forward to continued progress and will provide further updates as the study advances. 

For More Information

To learn more about the Polymotion® Hip Resurfacing System and the IDE study, please contact: cs@jointmedica.com